Poll Findings Highlight the Most Anticipated GU Cancer Abstracts at ASCO 2026

As the 2026 ASCO Annual Meeting draws near, anticipation is building among the genitourinary (GU) oncology world that data presented during the meeting which will span treatment intensification, de-escalation, adjuvant immunotherapy, and emerging biomarker technology will significantly push the field forward. To determine which abstracts have garnered the most interest, OncLive® conducted social media polls across LinkedIn and X.

Poll: Which GU cancer area are you the most excited to learn more about during the 2026 ASCO Annual Meeting?

• Renal cell carcinoma (RCC)
• Prostate cancer
• Bladder cancer
• Other

Respondents on LinkedIn (n = 30) indicated that bladder cancer was the disease space that they would be watching the most closely during the meeting. Prostate cancer (30%) was the second-most anticipated area, followed by RCC (23%) and other GU malignancies.

Poll: Which GU cancer abstract are you most excited to see presented at the 2026 ASCO Annual Meeting?

• LBA5007: TALAPRO-3
• LBA1: PROTEUS final analysis
• 4507: EV-302 3.5-year follow-up
• LBA4511: RAMPART

In terms of which specific abstracts were the most anticipated, LBA1, which will report the final analysis of the phase 3 PROTEUS trial (NCT03767244), received 38% of the vote to lead the field (n = 24). Abstract 4507 on the phase 3 EV-302 study (NCT04223856) earned 33% of the vote, with LBA5007 (21%) and LBA4511 (8%), covering the phase 3 TALAPRO-3 (NCT04821622) and RAMPART (NCT03288532) trials, respectively, also receiving votes. On X, LBA1 and LBA4511 received 1 vote each.

Based on these poll data, OncLive collected a list of the most anticipated GU abstracts being presented at the 2026 ASCO Annual Meeting. Read on for more insights on each study.

LBA5007: TALAPRO-3: Talazoparib (TALA) + enzalutamide (ENZA) compared with placebo (PBO) + ENZA for the treatment of patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) harboring homologous recombination repair (HRR) gene alterations

Presentation time: May 30, 2026, 5:12 pm CT

The primary end point of TALAPRO-3, which evaluated talazoparib (Talzenna) plus enzalutamide (Xtandi) vs enzalutamide alone in HRR-mutated mCSPC, was met according to a March 2026 press release. This presentation will explore additional data, including subgroup and OS findings.

LBA1: Perioperative (neoadjuvant and adjuvant) apalutamide (APA) + androgen deprivation therapy (ADT) vs placebo (PBO) + ADT with radical prostatectomy (RP) in high-risk localized or locally advanced prostate cancer (HR LPC/LAPC): Final analysis of the PROTEUS phase 3 study

Presentation time: May 31, 2026, 1:05 pm CT

If the apalutamide-containing regimen displays a pathologic complete response and metastasis‑free survival benefit vs the comparator arm it could offer a new standard of care in this patient population. This study tracts with the theme of perioperative intensification with androgen receptor pathway agents and could shift the treatment of patients with high-risk localized disease.

Abstract 4507: Enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): 3. 5-year follow-up and response analyses from the phase 3 EV-302 study

Presentation time: May 29, 2026, 4:57 pm CT

Prior data from EV-302 cemented enfortumab vedotin-ejfv (Padcev) in combination with pembrolizumab (Keytruda) as a standard first-line treatment for locally advanced/metastatic urothelial cancer. This update is slated to provide insights into whether the progression-free survival and overall survival benefits vs chemotherapy are durable and if any new safety signals have emerged with longer follow-up.

LBA4511: Durvalumab monotherapy versus active monitoring for resected primary renal cell carcinoma in RAMPART: An international, phase 3, randomized controlled trial

Presentation time: May 30, 2026, 8:24 am CT

RAMPART compared durvalumab (Imfinzi) monotherapy with active monitoring for the treatment of patients with resected primary RCC. Data from Arm B of the study will help to elucidate whether durvalumab can join the adjuvant treatment landscape. The study will also examine the addition of tremelimumab (Imjudo) to durvalumab in this setting.

Want to learn more about why these abstracts are generating excitement? Check out this preview article featuring exclusive expert insights and visit our conference coverage page for daily updates on these presentations and more throughout the meeting.